PDK4 knockdown suppresses osteoclast differentiation in osteoporosis through glycolytic flux suppression and AMPK activation
Bone · 2026-08 · 209 · 117911
DOI: 10.1016/j.bone.2026.117911 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bone, 2026-08. Verfasst von Yanling Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Shanghai Eighth People's Hospital, No. 8 Caobao Road, Xuhui District, Shanghai, 200235, China. Hauptthemen laut MEDLINE: Glycolysis, Osteoclasts, Cell Differentiation, AMP-Activated Protein Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Osteoporosis (OP) is a metabolic bone disorder primarily driven by excessive osteoclast-mediated bone resorption. Metabolic reprogramming, particularly a shift toward glycolysis, is crucial for osteoclast differentiation. However, the key regulators linking metabolism to bone resorption remain incompletely defined. METHODS: Bioinformatic analysis identified pyruvate dehydrogenase kinase 4 (PDK4) as a key glycolysis-associated gene in OP. Its role was validated using PDK4-knockdown RAW264.7 cells stimulated with receptor activator of nuclear factor kappa-B ligand (RANKL) and ovariectomized (OVX) rat models treated with PDK4-knockdown lentivirus, with or without the AMP-activated protein kinase (AMPK) inhibitor Dorsomorphin in each setting. Western blot was conducted to assess the expression of osteoclast differentiation markers and glycolysis-associated proteins. Glycolytic flux was determined by measuring glucose uptake, intracellular ATP, and lactate levels. Bone microstructure was evaluated by micro-computed tomography, while osteoclast activity was examined by tartrate-resistant acid phosphatase (TRAP) staining. RESULTS: PDK4 was significantly upregulated in RANKL-induced osteoclasts. PDK4 knockdown suppressed the expression of osteoclast differentiation markers and glycolytic flux in vitro. Mechanistically, PDK4 silencing activated the AMPK pathway. The anti-osteoclastic effects of PDK4 knockdown were reversed by the AMPK inhibitor Dorsomorphin. In OVX rats, PDK4 knockdown ameliorated bone loss, reduced osteoclast activity and markers, and suppressed glycolysis-associated protein expression in femur tissues. These therapeutic benefits were again negated by co-administration of Dorsomorphin. CONCLUSION: PDK4 knockdown suppresses osteoclastogenesis and OP progression by suppressing glycolysis via activating the AMPK pathway. Targeting the PDK4-AMPK-glycolysis axis presents a novel metabolic strategy for OP treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Shanghai Eighth People's Hospital, No. 8 Caobao Road, Xuhui District, Shanghai, 200235, China.
- Department of General Practice, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China.
- Department of Geriatrics, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. Electronic address: jamesjp801013@163.com.
Zitieren
APA
Huang, Y., Zhou, R., Liang, R., & Shen, J. (2026). PDK4 knockdown suppresses osteoclast differentiation in osteoporosis through glycolytic flux suppression and AMPK activation. Bone, 209, 117911. https://doi.org/10.1016/j.bone.2026.117911
Vancouver
Huang Y, Zhou R, Liang R, Shen J. PDK4 knockdown suppresses osteoclast differentiation in osteoporosis through glycolytic flux suppression and AMPK activation. Bone. 2026;209:117911. doi:10.1016/j.bone.2026.117911
BibTeX
@article{Huang2026,
author = {Huang, Yanling and Zhou, Rong and Liang, Rulian and Shen, Jiping},
title = {PDK4 knockdown suppresses osteoclast differentiation in osteoporosis through glycolytic flux suppression and AMPK activation},
journal = {Bone},
year = {2026},
volume = {209},
pages = {117911},
doi = {10.1016/j.bone.2026.117911}
}
EUVIMED